| Literature DB >> 32093046 |
Gabriele Serreli1, Monica Deiana1.
Abstract
The olive-oil-centered Mediterranean diet has been associated with extended life expectancy and a reduction in the risk of age-related degenerative diseases. Extra virgin olive oil (EVOO) itself has been proposed to promote a "successful aging", being able to virtually modulate all the features of the aging process, because of its great monounsaturated fatty acids content and its minor bioactive compounds, the polyphenols above all. Polyphenols are mostly antioxidant and anti-inflammatory compounds, able to modulate abnormal cellular signaling induced by pro-inflammatory stimuli and oxidative stress, as that related to NF-E2-related factor 2 (Nrf-2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), which have been identified as important modulators of age-related disorders and aging itself. This review summarizes existing literature about the interaction between EVOO polyphenols and NF-κB and Nrf-2 signaling pathways. Reported studies show the ability of EVOO phenolics, mainly hydroxytyrosol and tyrosol, to activate Nrf-2 signaling, inducing a cellular defense response and to prevent NF-κB activation, thus suppressing the induction of a pro-inflammatory phenotype. Literature data, although not exhaustive, indicate as a whole that EVOO polyphenols may significantly help to modulate the aging process, so tightly connected to oxidative stress and chronic inflammation.Entities:
Keywords: NF-κB; aging; anti-inflammatory activity; antioxidants; extra virgin olive oil; hydroxytyrosol; oleuropein; polyphenols; tyrosol
Mesh:
Substances:
Year: 2020 PMID: 32093046 PMCID: PMC7072812 DOI: 10.3390/cells9020478
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Extra-virgin olive oil (EVOO) main components.
EVOO polyphenols and modulation of Nrf-2 and antioxidant enzymes.
| Compound or Diet Supplement Tested | In Vivo/In Vitro Model | Concentration Tested | Effects | References |
|---|---|---|---|---|
|
| ||||
| Diet with 10% olive oil with high (HP) or low (LP) phenol content | Senescence-accelerated mouse-prone 8 | Pelletized Western-type diet with 20% fat, in which 10% of fat was from olive oil HP (532 mg gallic acid/kg oil) or LP (44 mg gallic acid/kg oil) | mRNA levels of antioxidant genes were significantly increased in heart tissue of the HP with respect to the LP group | [ |
| High-fat diet (HFD)-fed male mice C57BL/6J | 5 mg/kg daily | Maintenance of the activity of Nrf-2 at normal levels, reduction of the drop of PPAR-α activity and attenuation of the NF-κB activation | [ | |
| HT | High-fat diet (HFD)-fed male mice C57BL/6J | 10–50 mg/kg daily | Elevation of liver and muscle GST activity | [ |
| 60-days old Wistar male rats | 7.5 mg/kg/day for 30 days | Inefficacy to enhance GPx and GSH concentration. Increasing of oxidative stress in heart tissue, perhaps due to too high concentrations | [ | |
| Male Wistar rats with TCDD (2,3,7,8-tetrachlorodibenzo- | 0.5 mg/kg, oral | Restoration of the level of CAT, GPx, HO-1 and NQO1 activities in rat liver | [ | |
| Oleuropein | Spontaneously hypertensive rats (SHR) | Eight-weeks administration of 60 mg/kg daily | Increase of the levels of Nrf-2 dependent phase II enzymes NQO-1 and HO-1 | [ |
| Tyr | Mouse model of acute lung injury | 240 mg/kg | Improvement of (HO)-1 expression related to Nrf-2 activation | [ |
| Olive oil | Male Wistar rats with TCDD (2,3,7,8-tetrachlorodibenzo- | 10 mL/kg, oral | Restoration of the level of NQO1, CAT, HO-1 and GPx activities in rat liver | [ |
| Olive oil or its hydrophilic fraction | Male adult Wistar rats | 300 µL/ day | Increased the levels of CAT, GPx, GR and SOD enzymes | [ |
| EVOO | 12 to 16-wk-old male OF1 mice | 50 µL/day | Increased the levels of GPx and CAT | [ |
| Elderly humans (aged 65–96 years) | 50 mL/day | Significant raise of CAT was found in erythrocytes and, conversely, a decrease in GPx and SOD levels | [ | |
|
| ||||
| Macrophages RAW264.7 stimulated with LPS | 10 μM | Induction of Nrf-2 nuclear translocation | [ | |
| Macrophages J774 A.1-mediated oxidation of LDL | 0.5 mM | Preservation of GPx and GR mRNA expression | [ | |
| Human hepatocarcinoma HepG2 cells | 0.5, 1, 5 and 10 µM | Increase of the activity and the expression of GPx, GR and GST. Increase of Nrf-2 expression | [ | |
| Human hepatocarcinoma HepG2 cells | 10–40 µM | Keeping of GSH concentration and increase of GPx | [ | |
| HT | IMR-32 human neuroblastoma cells | 5 µM | Upregulation of Nrf-2 expression | [ |
| Caco-2 cells treated with acrylamide | 5–40 µM | Keeping of GSH concentration and increase of GPx | [ | |
| PC12 pheochromocytoma cells treated with 6-OHDA | 0–50 μM | Increase of the expression of HO-1, GCL, NQO1 and thioredoxin reductase following activation of the Keap1-Nrf-2 pathway | [ | |
| Retinal pigmented epithelium ARPE-19 cells | 100 μM | Preservation of Nrf-2 levels and antioxidant enzymes HO-1, NQO-1 | [ | |
| Tyr | Macrophages J774 A.1-mediated | 0.5 mM | Preservation of GPx and GR mRNA expression | [ |
Modulation of Akt, MAPK, and NF-κB pathway by EVOO polyphenols.
| Compound or Diet Supplement Tested | In Vivo/In Vitro Model | Concentration Tested | Effects | References |
|---|---|---|---|---|
|
| ||||
| HT | Rat brain from adult male Sprague-Dawley rats | 6 weeks administration 100 mg/kg/ daily | Modulation of NF-κB p65 subunit and caspase-3 levels | [ |
| High-fat diet (HFD)-fed mice | 5 mg/kg | NF-κB and PPAR-α down-regulation in the liver | [ | |
| EVOO | Female BALB/c mice with systemic lupus erythematosus (SLE)-like disease | 10% of oil in a complex diet | Inhibition of MAPK, JAK/STAT and NF-κB pathways in splenocytes | [ |
| VOO | Peripheral blood mononuclear cells of humans(19 men, 30 women) | 40 mL during breakfast | Limitation of NF-κB postprandial gene expression | [ |
| Tyr | BALB/c mice orally administered with LPS | 0.1–10 mg/kg | Inhibition of phosphorylated-IκBα and NF-κB traslocation into the nucleus | [ |
|
| ||||
| Tyr glucuronide | Caco-2 cells | 1 µM | Inhibition of IĸBα degradation and of p38 and ERK1/2 activation. No effects on Akt phosphorylation | [ |
| EVOO phenolic extracts | Caco-2 cells | 5–25 μg/mL | . Inhibition of p38 and ERK1/2 activation and of IĸBα degradation | [ |
| Human sinovial SW982 cells | 12.5–50 µM | Inhibition of MAPKs phosphorylation and NF-κB activation | [ | |
| Mouse mammary epithelial cells stimulated with | 10–40 μg/mL | Attenuation of NF-κB activation by downregulating MAPK p38, JNK and ERK1/2 activation | [ | |
| HT | Human hepatocarcinoma HepG2 cells | 0–400 µM | Inhibition of NF-κB and PI3/AKT pathways activation | [ |
| HT-29 intestinal cells | 200 μM | Decrease of NF-ĸB expression by modulating ERK 1/2 and Akt/PKB | [ | |
| Macrophages J774 A.1 stimulated with LPS | 50–200 μM | Prevention of NF-κB traslocation into the nucleus | [ | |
| Oleuropein | Monocyte-like THP-1 cells | 0–50 μM | Decrease of NF-ĸB expression | [ |
Inhibition of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) over-expression by EVOO polyphenols.
| Compound or Diet Supplement Tested | In Vivo/In Vitro Model | Concentration Tested | Effects | References |
|---|---|---|---|---|
|
| ||||
| Tyr | BALB/c mice orally administered with LPS | 0.1–10 mg/kg | Suppression of iNOS, COX-2 expression and phosphorylated- IκBα | [ |
| HT | Carrageenan-induced rat paw edema model | 500 mg/kg | Selective COX-2 inhibition | [ |
| EVOO phenolic extract enriched with HT | Diet-dextran sodium sulfate (DSS) mice | 40 mg/kg | COX-2 suppression after inhibition of NF-κB and MAPK pathways | [ |
|
| ||||
| Tyr glucuronide | Caco-2 cells | 1 µM | Inhibition of LPS-induced NO over-release and iNOS expression. Inhibition of p38 and ERK1/2 activation and of IĸBα degradation | [ |
| Caco-2 cells | 5–25 μg/mL | Inhibition of LPS-induced NO over-release and iNOS expression. Inhibition of p38 and ERK1/2 activation and of IĸBα degradation | [ | |
| EVOO phenolic extracts | Macrophages J774 A.1 stimulated with LPS | 50–150 μg/mL | Inhibition of NO over-production and of COX-2 and iNOS expression | [ |
| Peritoneal macrophage of mice stimulated with LPS | 25–50 μg/mL | Induction of a significant downregulation of iNOS and COX-2 through reduced nuclear translocation of NF-kB following MAPK phosphorylation | [ | |
| Undifferentiated Caco-2 cells | 50 μg/mL | Inhibition of CREB and p38 phosphorylation and consequent reduction in COX-2 expression | [ | |
| HT | Macrophages RAW264.7 stimulated with LPS | 10 μM | Inhibition of NO over-release and of iNOS expression | [ |
| Macrophages J774 A.1 stimulated with LPS | 50–200 μM | Down-regulation of COX-2 and iNOS gene expression by preventing NF-κB translocation into the nucleus | [ | |
| Undifferentiated Caco-2 cells | 5–200 µM | Inhibition of ERK1/2 phosphorylation. No effects on p38 activity and COX-2 expression | [ | |
| LPS-activated peripheral blood mononuclear cells | 100 µM | Reduction of COX-2 gene expression and PGE2 secretion | [ | |
| Oleuropein | Macrophages RAW264.7 stimulated with LPS | 10 μM | Inhibition of PGE2 and NO over-production. Reduction of iNOS and COX-2 expression | [ |
| LPS-activated human primary osteoarthritis chondrocytes | 1–5 μM | Inhibition of NO over-production following inhibition of iNOS expression through MAPK modulation | [ | |
| Oleocanthal | Hepatocellular carcinoma (Huh7, PLC/PRF/5, HepG2 and Hep3B) and colorectal carcinoma (HT29, SW480) models | 25 μM | Inhibition of COX-2 expression | [ |
| HT-29 intestinal cells | 1–5 μg/mL | Induction of apoptosis through COX-2 suppression and AMPK activation | [ |
Figure 2Main molecular pathways involved in EVOO polyphenols health effects in aging.